Vistagen Therapeutics, Inc. (VTGN)
NASDAQ: VTGN · Real-Time Price · USD
0.2670
+0.0070 (2.69%)
Aug 27, 2026, 10:46 AM EDT - Market open
Vistagen Therapeutics Employees
Vistagen Therapeutics had 41 employees as of June 30, 2026. The number of employees decreased by 16 or -28.07% compared to the same quarter last year.
Employees
41
Change
-16
Growth
-28.07%
Revenue / Employee
$61,000
Profits / Employee
-$1,649,268
Market Cap
11.85M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Jun 30, 2026 | 41 | -16 | -28.07% | 41 | 0 |
| Mar 31, 2026 | 41 | -16 | -28.07% | 41 | 0 |
| Dec 31, 2025 | 59 | 11 | 22.92% | 59 | 0 |
| Sep 30, 2025 | 59 | 14 | 31.11% | 59 | 0 |
| Jun 30, 2025 | 57 | 16 | 39.02% | 57 | 0 |
| Mar 31, 2025 | 57 | 17 | 42.50% | 56 | 1 |
| Dec 31, 2024 | 48 | 11 | 29.73% | 48 | 0 |
| Sep 30, 2024 | 45 | 12 | 36.36% | 45 | 0 |
| Jun 30, 2024 | 41 | 9 | 28.13% | 41 | 0 |
| Mar 31, 2024 | 40 | 6 | 17.65% | 39 | 1 |
| Dec 31, 2023 | 37 | 5 | 15.63% | 37 | 0 |
| Sep 30, 2023 | 33 | -1 | -2.94% | 33 | 0 |
| Jun 30, 2023 | 32 | -6 | -15.79% | 32 | 0 |
| Mar 31, 2023 | 34 | -2 | -5.56% | 33 | 1 |
| Dec 31, 2022 | 32 | 1 | 3.23% | 32 | 0 |
| Sep 30, 2022 | 34 | 8 | 30.77% | 34 | 0 |
| Jun 30, 2022 | 38 | 14 | 58.33% | 38 | 0 |
| Mar 31, 2022 | 36 | 15 | 71.43% | 36 | 0 |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| CytoMed Therapeutics | 42 |
| Senti Biosciences Holdings | 39 |
| Lunai Bioworks | 29 |
| Daré Bioscience | 24 |
| IN8bio | 18 |
| Moleculin Biotech | 17 |
| Theriva Biologics | 16 |
| Kiora Pharmaceuticals | 13 |
VTGN News
- 13 days ago - Vistagen Reports Fiscal Year 2027 First Quarter Financial Results and Corporate Update - GlobeNewsWire
- 13 days ago - Vistagen Therapeutics Earnings release: Q1 2027 - Filings
- 13 days ago - Vistagen Therapeutics Quarterly report: Q1 2027 - Filings
- 21 days ago - Vistagen announces topline results from fasedienol repeat dose study - TheFly
- 21 days ago - Vistagen Announces Topline Results for Repeat Dose Study of Fasedienol for Acute Treatment of Social Anxiety Disorder - GlobeNewsWire
- 23 days ago - SRX Global acquires stake in Vistagen - TheFly
- 27 days ago - Vistagen Appoints Douglas J. Williamson to its Board of Directors - GlobeNewsWire
- 27 days ago - Vistagen Therapeutics Proxy statement: Proxy filing - Filings